News

The real-world use of Kalydeco (ivacaftor) effectively eased disease severity in people with cystic fibrosis (CF) who had certain disease-causing mutations, according to a study that included patients with mutations for which Kalydeco was approved in the U.S. in 2017 based largely on laboratory data. “This study adds…

A new small molecule, called VOMG, showed good antimicrobial activity against Mycobacterium abscessus, a bacterium that can cause serious infections in people with cystic fibrosis (CF). “The bactericidal and eradicating properties of VOMG … strongly reinforce the potential of VOMG in the treatment of pulmonary infections especially in CF individuals,…

A high dose of vitamin D combined with inulin, a prebiotic, led to improvements in the diversity of bacteria living in the airway and lungs of people with cystic fibrosis (CF) in a small clinical trial. The findings in the study, “Impact of high-dose cholecalciferol (vitamin…

While physical health and life quality gains can be evident in people using CFTR modulators, a group of disease-modifying therapies for cystic fibrosis (CF), their mental well-being needs more attention, according to the Wellness in the Modulator Era (Well-ME) study. Nearly 1 in every 4 patients reported poorer…

Men and patients diagnosed with cystic fibrosis (CF) earlier in life have higher lung function and greater lung function variability, according an analysis spanning over 20 years of data from the U.K. Cystic Fibrosis Registry. Lung function variability increased in men and women with CF after age 40, a…

A researcher at the University of California, Los Angeles (UCLA) has been awarded the Elizabeth Nash Postdoctoral Fellowship to develop a targeted cystic fibrosis (CF) gene therapy delivery system, the university announced. The two-year, $65,000-per-year fellowship, awarded annually by the Cystic Fibrosis Research Institute to support new…

An Emory University program has been awarded $2 million toward optimizing the effectiveness of U.S. newborn screening programs, which help identify serious health conditions such as cystic fibrosis (CF) at birth. The four-year funding opportunity comes through a cooperative agreement with the U.S. Health Resources and Services Administration…

Researchers have uncovered a mechanism by which Pseudomonas aeruginosa and Aspergillus fumigatus — two common infection-causing microbes in the lungs of people with cystic fibrosis (CF) — are able to…

SARS-CoV-2, the virus that causes COVID-19, appears to induce the loss of CFTR protein in a cell-based airway model, replicating the inflammatory state seen in the lungs of people with cystic fibrosis (CF), a study suggested. Treating cells with cardiac glycosides, a class of medicines that block the virus…

Destiny Pharma is launching a research program to test a potential therapy derived from its XF drug platform for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). The program will test the potency of an experimental treatment known as XF-73 in MRSA samples from CF…